Yasaman Eslaamizaad, MD
Pulmonary Disease · Salem, ORNPI 1770921470
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,808 of the $3,247 with a category attached, or 86.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $896 and has fallen 53.6% since, to $416 in 2025.
Across 118 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$743
- AstraZeneca$445
- Boston Scientific$439
- Intuitive Surgical$309
- Boehringer Ingelheim$268
- La Jolla Pharmaceutical Company$209
- plus $834 from 17 others
What the payments were for
- Travel & lodging$43914%
- Food & beverage$2,80886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $743 |
| AstraZeneca | 18 | $445 |
| Boston Scientific | 2 | $439 |
| Intuitive Surgical | 2 | $309 |
| Boehringer Ingelheim | 8 | $268 |
| La Jolla Pharmaceutical Company | 4 | $209 |
| Merck | 8 | $142 |
| United Therapeutics Corporation | 5 | $138 |
| Novartis | 5 | $84 |
| Actelion Pharmaceuticals US, Inc. | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Mannkind Corporation | 3 | $45 |
| Genentech USA, Inc. | 2 | $36 |
| Grifols USA, LLC | 2 | $35 |
| Amgen | 2 | $33 |
| Mylan Specialty L.p. | 2 | $30 |
| Insmed, Inc. | 2 | $29 |
| Sanofi | 2 | $28 |
| Philips North America LLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| CSL Behring | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXPECT$439
- Da Vinci Surgical System$309
- OFEV$128
- NUCALA$125
- TEZSPIRE$122
How this compares
$3,247 in reported general payments places this provider in the 75th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 403 | $287,000 |
| Breo ElliptaFluticasone/Vilanterol | 136 | $59,759 |
| Spiriva RespimatTiotropium Bromide | 58 | $33,159 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $18,561 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 86 | $17,190 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $12,897 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $11,400 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,050 |
| Spiriva HandihalerTiotropium Bromide | 19 | $10,793 |
| Roflumilast | 63 | $8,233 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $8,121 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 269 | $6,338 |
| DuleraMometasone/Formoterol | 17 | $5,478 |
| Varenicline Tartrate | 22 | $4,154 |
| Budesonide | 12 | $3,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $743 | $359,656556 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $268 | $44,55882 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $445 | $29,61188 claims |
| MerckDulera | $142 | $5,47817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Salem
- Kamran FirooziSalem$9K
- Steven MarvelSalem$8K
- Nimeshkumar MehtaSalem$7K
- Bijaya ShresthaSalem$4K
- Martin JohnsonSalem$4K
- Kavan RamachandranSalem$3K
- Fayez BaderSalem$2K
- James ParosaSalem$1K
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.